IL17A and metabolic dysfunction-associated steatotic liver disease: We can hypothesize that increases in IL-17, IL-23 and IL-33 in septic patients with MASLD might explain frequent sepsis complications previously reported in other cohorts, but also long-term immunological dysfunction in sepsis survivors, which was not examined here but might facilitate subsequent liver disease progression.